Uterine Fibroids (Leiomyoma)MyoMwaNCT07780019
Microwave Ablation of Uterine Fibroids
An observational study of Uterine Fibroids (Leiomyoma), run by Turku University Hospital at 1 site in Finland.
Trial summary
This prospective observational study aims to evaluate the effectiveness and acceptability of percutaneous or vaginal ultrasound guided microwave ablation for the treatment or symptomatic uterine fibroids. We will include 100 women. Read more about this study
- Who is it for?
- Ages 18 to 56 years, women only
- Conditions the study is for
- Uterine Fibroids (Leiomyoma)
- What is being tested?
- microwave ablation
- Type of treatment
- Surgery or procedure
- How many people
- 100 participants
- Where
- 1 siteFinland
- Study dates
- 1 May 2026to Dec 2034
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 56 years
- Women only
- No healthy volunteers
- Adult
Study population: patients undergoing mwa for symptomatic uterine fibroids will be recruited for this study
Who may be able to join
- symptomatic fibroids
- premenopausal status
- acceptable risks for general anestesia or sedation
- willing to undergo mwa treatment and participate in the study
Who cannot join
- postmenopausal status
- bleeding disorder with increased risk of bleeding
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective Observational Study of Microwave Ablation of Uterine Fibroids (MyoMwa)
This prospective observational study aims to evaluate the effectiveness and acceptability of percutaneous or vaginal ultrasound guided microwave ablation for the treatment or symptomatic uterine fibroids. We will include 100 women.
- Conditions
- Uterine Fibroids (Leiomyoma)
- Being tested
- microwave ablation
- Keywords
- microwave ablation
- Medical subject headings
- Leiomyoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
microwave ablationProcedure or surgery
ultrasound guided percutaneus microwave ablation
| Study group | Role | What they receive |
|---|---|---|
| patients with symptomatic uterine fibroids | Patients with symptomatic uterine fibroids, who will undergo microwave ablation of fibroids as a clinical treatment are recruited in this study. Receives: Procedure: microwave ablation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Symptom severity of uterine fibroids and quality of life
Score of validated form Uterine Fibroid symptom - Quality of life questinnaire. minimum 0, maximum 100 where higher scores indicate higher symptom severity
Measured: 12 months
suitability of mwa for general fibroid population
objective and subjective outcome of mwa in different fibroid types, sizes and locations
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2026
- Study start1 May 2026
- Primary completionDec 2031 (estimated)
- Study completionDec 2034 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Uterine Fibroids (Leiomyoma)Studies of the same condition, open and under way.
- More trials run by Turku University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Turku University Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Kirsi Joronen, Turku University Hospital
- Investigators
- Kirsi Joronen, Principal investigator, Turku University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07780019
- Sponsor's protocol ID
- T2026/43353
- Acronym
- MyoMwa
- Status last verified
- Aug 2026
- First submitted
- 12 Aug 2026
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Observational Study of Microwave Ablation of Uterine Fibroids (MyoMwa)
- ClinicalTrials.gov ID
- NCT07780019
- Acronym / sponsor ID
- MyoMwa / T2026/43353
- Conditions
- Uterine Fibroids (Leiomyoma)
- Keywords
- microwave ablation
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Turku University HospitalOther government
- Study start
- 1 May 2026 (actual)
- Primary completion
- Dec 2031 (estimated)
- Study completion
- Dec 2034 (estimated)
- First posted
- 21 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective observational study aims to evaluate the effectiveness and acceptability of percutaneous or vaginal ultrasound guided microwave ablation for the treatment or symptomatic uterine fibroids. We will include 100 women.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patients with symptomatic uterine fibroids | – | Procedure: microwave ablationPatients with symptomatic uterine fibroids, who will undergo microwave ablation of fibroids as a clinical treatment are recruited in this study. |
Who may qualify
- Ages
- 18 to 56 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- patients undergoing mwa for symptomatic uterine fibroids will be recruited for this study
Key inclusion criteria (4 listed)
- symptomatic fibroids
- premenopausal status
- acceptable risks for general anestesia or sedation
- willing to undergo mwa treatment and participate in the study
Key exclusion criteria (2 listed)
- postmenopausal status
- bleeding disorder with increased risk of bleeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| microwave ablationultrasound guided percutaneus microwave ablation | Procedure or surgery | patients with symptomatic uterine fibroids |
Primary outcome
Symptom severity of uterine fibroids and quality of life
Time frame: 12 months
Score of validated form Uterine Fibroid symptom - Quality of life questinnaire. minimum 0, maximum 100 where higher scores indicate higher symptom severity
suitability of mwa for general fibroid population
Time frame: 12 months
objective and subjective outcome of mwa in different fibroid types, sizes and locations
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
Related trials for Uterine Fibroids (Leiomyoma)
Active, not recruiting
Prospective Study of TVRFA Treatment for FIGO Type 3-5 Uterine Fibroids
Leiomyoma (Uterine Fibroids)
RecruitingObservational study
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
Renal Tumor Histology, Cutaneous Leiomyoma
Active, not recruiting
Life Study: Lifestyle Intervention in Fibroid Elimination
Uterine Fibroid
Not yet recruiting
Office Hysteroscopy Versus Operating-room Hysteroscopy for Uterine Lesions
Uterine Polyps, Uterine Fibroids
RecruitingObservational study
Predictors of Success and Failure of v-NOTES Hysterectomy for Large and Very Large Uteri
Uterine Fibroids, Hysterectomy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kirsi Joronen principal investigator
Turku University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Uterine Fibroids (Leiomyoma), run by Turku University Hospital at 1 site in Finland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Symptom severity of uterine fibroids and quality of life (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.